Abstract
and identified to have 24-hour urine profiles. Of these individuals, 472 met inclusion criteria. There was no significant difference in the reduction of stone formation rates between those patients whose post-KCit urinary pH was > 6.5 (average pH 6.92) versus those patients whose pH was 6.5 (average pH 6.04). There was no statistically significant correlation between stone formation rate and pH among all subjects. Even among subjects who had a post-KCit urinary pH of >6.5, there was no correlation between increasing pH and stone formation rate. CONCLUSIONS: Concern exists that KCit therapy for recurrent nephrolithiasis may increase the risk of CaPhos stones, which are know to form in alkaline urine. While we did not have stone analyses in all of our patients who had been placed on KCit treatment, equally significant reduction in stone formation rates, especially in those patients with a urine pH > 6.5, suggests that this medication does not increase the risk of CaPhos stones. Further investigation is required to identify if there are any other risk factors which may promote CaPhos stone formation in patients on KCit with highly alkaline urine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
